Attached files
file | filename |
---|---|
EX-99.1 - CORPORATE PRESENTATION - MABVAX THERAPEUTICS HOLDINGS, INC. | mbvxex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 7,
2016
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-31265
|
|
93-0987903
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:
(858) 259-9405
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
ITEM 7.01
|
REGULATION FD DISCLOSURE.
|
On
December 7, 2016, the Chief Executive Officer of MabVax
Therapeutics Holdings, Inc. (the “Company”) gave an
updated corporate presentation to potential investors. The
presentation is attached hereto as Exhibit 99.1.
Forward-Looking Statements
Certain
statements in this Form 8-K and the Exhibit are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about data and other
information regarding our discovery platform and plans, drug
development (pre-clinical and clinical) plans, pipelines, timelines
and milestones, patient needs, mechanisms of action, market
opportunities, capital efficiency, management, external partnering
of products for additional capital, external funding, financial
results, current rate of spending, and patent rights. Actual events
or results may differ materially from our expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the
following: our discovery and (pre-)clinical drug development,
clinical trial and corporate development and partnering programs
could have unexpected or unfavorable results or results that fail
to meet our, or our investors’, expectations; these programs
could experience regulatory and other delays and/or unexpected
terminations; we may not be able to raise future capital or
receiving funding as expected or as needed due to market factors or
Company results or both; patient needs and market opportunities may
change and/or fail to meet expectations; we may not be able to
partner our products or receive or defend patent rights that are
important to our business.
Detailed
information regarding these and other factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this report may be found in the Company's periodic
filings with the Securities and Exchange Commission, including the
factors described in the section entitled "Risk Factors" in its
annual report on Form 10-K for the fiscal year ended December 31,
2015, and its Registration Statement on Form S-1 as amended through
August 16, 2016.
The
information disclosed under this Item 7.01, including Exhibit 99.1
hereto, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, nor shall it be incorporated by
reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended, except as
expressly set forth in such filing.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits.
The
exhibit listed in the following Exhibit Index is furnished with
this Current Report on Form 8-K.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Corporate
Presentation as amended through December 7, 2016
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
MABVAX THERAPEUTICS HOLDINGS, INC.
|
|
|
Dated:
December 7, 2016
|
/s/ J. David
Hansen
|
|
J David
Hansen
|
|
Chairman and Chief Executive Officer
|